Stock events for Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals' stock has been impacted by several key events, including its acquisition by Servier for $2.5 billion, strong financial results and outlook with significant revenue growth, a Q4 2025 earnings miss, M&A speculation, the acquisition of Mersana Therapeutics, and insider selling by Michael Vasconcelles.
Demand Seasonality affecting Day One Biopharmaceuticals, Inc.’s stock price
While oncology prescribing patterns can experience typical holiday seasonality, Day One Biopharmaceuticals' product, OJEMDA, demonstrated resilience. Prescription volumes for OJEMDA increased in Q4 2025 despite these seasonal trends, indicating strong and consistent patient demand.
Overview of Day One Biopharmaceuticals, Inc.’s business
Day One Biopharmaceuticals, Inc. is focused on developing targeted therapies for genetically defined cancers, particularly in pediatric oncology. Its major product candidates include Tovorafenib (OJEMDA), an oral kinase inhibitor in Phase II and III trials with significant commercial success; Pimsertib, an oral MEK inhibitor; DAY301, a PTK7-targeted antibody-drug conjugate in Phase 1a trials; and Emi-Le, an antibody-drug conjugate targeting B7-H4 in Phase 1 trials.
DAWN’s Geographic footprint
Day One Biopharmaceuticals, Inc. is headquartered in Brisbane, California, United States, and plans to expand OJEMDA commercially beyond the U.S. through global partnerships.
DAWN Corporate Image Assessment
Day One Biopharmaceuticals has maintained a largely positive brand reputation, with analysts giving eight "Buy" ratings and one "Hold" rating. The company's reputation is bolstered by the strong commercial performance of OJEMDA, the acquisition of Mersana Therapeutics, and the acquisition offer by Servier.
Ownership
Day One Biopharmaceuticals, Inc. has significant institutional ownership, with 246 institutional owners holding a total of 85,384,436 shares, including major holders like BlackRock, Inc., Atlas Venture Life Science Advisors, LLC, and Vanguard Group Inc. Significant individual and insider owners include Ai Day1 LLC and Julie Grant Papanek.
